The Tyrosine Kinase Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Tyrosine Kinase Inhibitors Market:
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report
According to The Business Research Company’s Tyrosine Kinase Inhibitors Global Market Report 2024, The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $53.72 billion in 2023 to $58.69 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to discovery of tyrosine kinases, understanding cancer signaling pathways, approval of imatinib (gleevec), clinical success of early tkis, investment in research and development.
The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $81.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of cns-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.
The increasing prevalence of cancer is expected to propel the growth of the tyrosine kinase inhibitors market going forward. Cancer refers to a broad collection of illnesses that begin in any organ or tissue of the body, where abnormal cells grow out of control, cross their usual boundaries to infect nearby body parts, and spread to other organs. The tyrosine kinase inhibitors are used in targeted therapy to target and kill cancer cell types by blocking tyrosine kinases that aid in preventing the growth of cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. Therefore, the increasing prevalence of cancer is driving the growth of the tyrosine kinase inhibitors market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp
The tyrosine kinase inhibitors market covered in this report is segmented –
1) By Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2) By Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3) By Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications
Top Major Players:
Pfizer Inc.
Johnson And Johnson Private Limited.
F. Hoffmann-La Roche AG
AbbVie Inc.
Bayer AG
North America was the largest region in the tyrosine kinase inhibitors market in 2023.
Product innovations are a key trend gaining popularity in the tyrosine kinase inhibitor market. Major companies operating in the tyrosine kinase inhibitor market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Novartis AG, a Switzerland-based pharmaceutical corporation, received approval from the Food and Drug Administration for the drug asciminib (Scemblix, Novartis AG) for individuals with chronic myeloid leukemia (Ph+ CML) that has the Philadelphia chromosome in the chronic phase (CP). Additionally, this inhibitor binds to a pocket different from the ATP-binding region of the kinase 9 to precisely and potently block BCR-ABL1. It offers the prospect of dual inhibition of BCR-ABL1 in conjunction with ATP-binding TKIs and the potential to overcome resistance to earlier TKIs.
The tyrosine kinase inhibitors market report table of contents includes:
1. Executive Summary
2. Tyrosine Kinase Inhibitors Market Characteristics
3. Tyrosine Kinase Inhibitors Market Trends And Strategies
4. Tyrosine Kinase Inhibitors Market - Macro Economic Scenario
5. Global Tyrosine Kinase Inhibitors Market Size and Growth
…
32. Global Tyrosine Kinase Inhibitors Market Competitive Benchmarking
33. Global Tyrosine Kinase Inhibitors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Tyrosine Kinase Inhibitors Market
35.Tyrosine Kinase Inhibitors Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The Tyrosine Kinase JAK Inhibitors Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the tyrosine kinase JAK inhibitors market includes AbbVie, Astellas Pharma, Celgene, CTI BioPharma, Eli Lilly, Galapagos, Gilead, Incyte, Novartis, Pfizer, Sanofi, Teva, Vertex, and others.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Tyrosine Kinase JAK Inhibitors Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/tyrosine-kinase-jak-inhibitors-market/download-sampleMarket DynamicsThe growth of the tyrosine kinase inhibitors can be attributed to the rising prevalence of cancer and autoimmune disease across the globe coupled with the expanding healthcare sector.
Rising adoption of tyrosine kinase inhibitors for the treatment of cancer because of specificity and various benefits over radiotherapy and chemotherapy is further expected to favor market growth.
Ongoing development of novel drugs for the treatment of cancer coupled with the rising investment in the healthcare and pharmaceutical industry by respective regulatory bodies is also projected to raise the market value over the forecast timeline.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the bruton tyrosine kinase (btk) inhibitors market include Johnson & Johnson, AstraZeneca, Roche, Sunesis, Takeda, Bristol- Myers Squibb, Gilead Sciences, AbbVie, Biogen, INNOCARE, ACEA Biosciences, Acerta Pharma.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/bruton-tyrosine-kinase-btk-inhibitors-market/download-sampleMarket DynamicsThe growing demand for chemotherapy-free management of B-cell malignancies is the main driver for this market's growth.
Several clinical studies to evaluate BTK inhibitors' efficacy to treat various forms of leukemia and lymphoma either as a single medication or in combination with other drugs, chemotherapy, or immunotherapy will broaden the market's scope.
BTK inhibitors' demand to treat autoimmune diseases like multiple sclerosis will continue to grow.
They are attractive therapeutic agents that are less likely to trigger antibody responses against the drug and consequent allergic reactions.
